Skip to content

US · BLTE · BIOTECHNOLOGY

Belite Bio, Inc (BLTE) intrinsic value and stock valuation

$127.38as of 2026-11-21 · Mkt cap 6.35B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Belite Bio, Inc DCF and intrinsic value

InvestorsCraft values BLTE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BLTE’s statements →

Belite Bio, Inc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92130 belitebio.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-77.61M
20202025
Free cash flow
-$-37.17M
20202025
Total equity
$770.5M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-84.21M-$-40M-$-31.67M-$-12.82M-$-9.8M
Net income-$-77.61M-$-36.14M-$-31.63M-$-12.65M-$-9.67M
EPSd-$-2.31M-$-1.18M-$-1.19M-$-633.13K-$-401.24K
Operating cash flow-$-36.99M-$-29.23M-$-29.84M-$-11.46M-$-7.47M
Capital expenditure-$-180K-$-150K-$-60K-$-390K-$-70K
Free cash flow-$-37.17M-$-29.39M-$-29.9M-$-11.85M-$-7.55M
Total assets$780.6M$152.1M$94.6M$44.3M$18.4M
Total debt$430K$540K$890K$870K$31.8M
Net debt-$-352.5M-$-31.14M-$-87.27M-$-41.22M$14.5M
Total equity$770.5M$145.8M$90.4M$41.5M-$-15.09M
Cash and short-term investments$492.4M$145.2M$88.2M$42.1M$17.3M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$45.4M$29.9M$24.8M$8.87M$7.42M
Selling, general and administrative expenses$38.8M$10.1M$6.82M$3.95M$2.38M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$84.2M$40M$31.7M$12.8M$9.8M
Cost and expenses$84.2M$40M$31.7M$12.8M$9.8M
Interest income$0.00$3.74M$70K$20K$10K
Interest expense$0.00$20K$30K$20K$0.00
Depreciation and amortization$460K$450K$400K$200K$30K
Ebitda-$-77.15M-$-35.67M-$-31.2M-$-12.43M-$-9.64M
Operating income-$-84.21M-$-40M-$-31.67M-$-12.82M-$-9.8M
Total other income/expenses, net$6.6M$3.86M$40K$170K$130K
Income before tax-$-77.61M-$-36.14M-$-31.62M-$-12.65M-$-9.67M
Income tax expense$0.00$10K$10K$0.00$0.00
Net income-$-77.61M-$-36.14M-$-31.63M-$-12.65M-$-9.67M
Weighted average shares outstanding$33.5M$30.5M$26.6M$20M$24.1M
Weighted average diluted shares outstanding$33.5M$30.5M$26.6M$20M$24.1M
Balance sheet
20252024202320222021
Cash and short-term investments$492.4M$145.2M$88.2M$42.1M$17.3M
Net receivables$720K$590K$870K$20K$20K
Inventory$0.00$0.00$0.00-$-20K$0.00
Total current assets$494.3M$147.1M$89.9M$42.8M$17.4M
Property, plant and equipment, net$780K$960K$1.3M$1.38M$90K
Goodwill and intangible assets$4.92M$3.99M$3.23M$30K$0.00
Long-term investments$280.2M$0.00$0.00$0.00$0.00
Total non-current assets$286.3M$5.06M$4.7M$1.47M$920K
Total assets$780.6M$152.1M$94.6M$44.3M$18.4M
Accounts payable$0.00$0.00$0.00$0.00$0.00
Short-term debt$240K$280K$620K$400K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$9.88M$6.05M$3.63M$2.1M$1.64M
Long-term debt$190K$260K$580K$670K$31.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$190K$260K$580K$670K$31.8M
Capital lease obligations$430K$540K$890K$870K$0.00
Total liabilities$10.1M$6.31M$4.21M$2.77M$33.4M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-185.26M-$-107.65M-$-71.5M-$-39.87M-$-27.22M
Accumulated other comprehensive income (loss)-$-540K-$-660K-$-370K-$-390K-$-200K
Total equity$770.5M$145.8M$90.4M$41.5M-$-15.09M
Total investments$419.7M$113.5M$0.00$0.00$0.00
Total debt$430K$540K$890K$870K$31.8M
Net debt-$-352.5M-$-31.14M-$-87.27M-$-41.22M$14.5M
Cash flow statement
20252024202320222021
Net income-$-77.61M-$-36.14M-$-31.63M-$-12.65M-$-9.67M
Depreciation and amortization$460K$450K$400K$200K$30K
Stock-based compensation$38.9M$8.99M$3.82M$1.48M$1.53M
Change in working capital$2.55M$1.13M-$-2.43M-$-490K$640K
Accounts receivable-$-70K$70K-$-70K-$-30K$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-36.99M-$-29.23M-$-29.84M-$-11.46M-$-7.47M
Investments in property, plant and equipment-$-180K-$-120K-$-60K-$-390K-$-70K
Acquisitions, net$0.00$0.00$0.00$0.00$20K
Net cash used for investing activities-$-305.11M-$-110.57M-$-60K-$-390K-$-60K
Common stock issued$292.9M$42.2M$77.2M$38M-$-580K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$663.2M$83.6M$76M$37M-$-580K
Net change in cash$321.3M-$-56.48M$46.1M$24.8M-$-8.27M
Cash at end of period$352.9M$31.7M$88.2M$42.1M$17.3M
Operating cash flow-$-36.99M-$-29.23M-$-29.84M-$-11.46M-$-7.47M
Capital expenditure-$-180K-$-150K-$-60K-$-390K-$-70K
Free cash flow-$-37.17M-$-29.39M-$-29.9M-$-11.85M-$-7.55M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Belite Bio, Inc

        Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.

        CEO
        Yu-Hsin Lin
        Employees
        41
        Beta
        -1.23

        Explore

        Frequently asked questions

        What is the intrinsic value of Belite Bio, Inc (BLTE)?

        InvestorsCraft does not currently publish an intrinsic value for BLTE. How the IC value is calculated.

        Is BLTE undervalued?

        InvestorsCraft does not publish an undervaluation signal for BLTE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.